BioCentury
ARTICLE | Finance

ASCO's early returns

Rounding up the winners and losers from ASCO 2015

June 8, 2015 7:00 AM UTC

While discussions about value and incremental data from late-stage checkpoint inhibitors dominated this year's American Society of Clinical Oncology meeting in Chicago, it's clear that investors also were on the lookout for - and willing to reward - early clinical data.

Ignyta Inc. (NASDAQ:RXDX) and ImmunoGen Inc. (NASDAQ:IMGN) were the biggest winners, with gains of more than 60% on Phase I data. ...